CONCORDBIO2024-10-012024-12-31 CONCORDBIO2024-10-012024-12-31 CONCORDBIO2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member CONCORDBIO2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member CONCORDBIO2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member CONCORDBIO2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member CONCORDBIO2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543960 CONCORDBIO NA Concord Biotech Limited Equity 2024-04-01 2025-03-31 2025-02-13 2025-01-24 INR Lakhs Third quarter 18:00:00 19:00:00 2025-02-13 2025-02-13 Not applicable Single segment Pharmaceuticals 2024-10-01 2024-12-31 Unaudited Consolidated 2442202000.00 147294000.00 2589496000.00 609560000.00 121900000.00 -207480000.00 346405000.00 974000.00 132640000.00 592297000.00 1596296000.00 993200000.00 0.00 993200000.00 236923000.00 15389000.00 252312000.00 0.00 740888000.00 0.00 0.00 0.00 18323000.00 759211000.00 -14501000.00 744710000.00 759211000.00 0.00 744710000.00 0.00 104616000.00 1 7.26 7.26 0.00 0.00 7.26 7.26 Notes to the statement of unaudited consolidated financial results for the quarter and nine months ended December 31, 2024: 1. The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on February 13, 2025. The Statutory Auditors of the company have carried out a limited review of the said results. 2. The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - Operating Segment . 3. The above consolidated financial results has been prepared in accordance with Indian Accounting Standards ( Ind AS ) notified under Section 133 of the Companies Act, 2013 read together with Companies (Indian Accounting Standards) Rules, 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India ( SEBI ). 4. The unaudited consolidated financial results of the company include information of joint venture company Concord Biotech Japan K.K. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 7702031000.00 350627000.00 8052658000.00 1840438000.00 456687000.00 -526969000.00 999679000.00 4338000.00 397569000.00 1773108000.00 4944850000.00 3107808000.00 0.00 3107808000.00 771461000.00 26079000.00 797540000.00 0.00 2310268000.00 0.00 0.00 0.00 2283000.00 2312551000.00 -15112000.00 2297439000.00 2312551000.00 0.00 2297439000.00 0.00 104616000.00 1 22.11 22.11 0.00 0.00 22.11 22.11 Others 327887000.00 Power and fuel 264410000.00 Others 944179000.00 Power and fuel 828929000.00 -14501000.00 -15112000.00 0.00 0.00 0.00 0.00